Search Results

Displaying Results 8801-8825 of 28135 "'FORM'"

May 22, 2026, 06:00 ET Yuchai's Flywheel Range Extension Technology Arrives in Hong Kong SAR, Setting a New Benchmark for Green Mobility

exchange regulations, competition, political, economic and social conditions around the world and in China, including those discussed in the Company's Form 20-Fs under the headings "Risk Factors", "Results of Operations" and "Business Overview" and other reports filed with the Securities and Exchange Commission

More news about: China Yuchai International


May 22, 2026, 03:53 ET Shanghai Electric Marks International Day for Biological Diversity with Localized Green Practices

fully connected to the grid and became commercially operational in September.The turbines, integrated with energy storage and photovoltaics to form a clean microgrid, generate 244 million kWh annually to power 32,000 residents while delivering more than 200 million kWh of green electricity to areas

More news about: Shanghai Electric


May 22, 2026, 03:09 ET Shanghai Electric Marks International Day for Biological Diversity with Localized Green Practices

fully connected to the grid and became commercially operational in September.The turbines, integrated with energy storage and photovoltaics to form a clean microgrid, generate 244 million kWh annually to power 32,000 residents while delivering more than 200 million kWh of green electricity to areas

More news about: Shanghai Electric


May 22, 2026, 03:00 ET KFC's KPRO Tops 300 Locations in China

"Risk Factor" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q) for additional detail about factors that could affect our financial and other results.About Yum China Holdings,

More news about: Yum China Holdings, Inc.


May 22, 2026, 02:04 ET China Daily: China-US ties seek a path beyond confrontation

editor-in-chief of Contemporary American Review, a Chinese academic journal published by the IAS, said US policy toward China is moving toward a more realistic form of competition based on recognition of China's strength. He attributed the shift partly to China's steady rise in comprehensive national strength, partly

More news about: China Daily


May 22, 2026, 00:58 ET 2026 ASCO Abstract Highlights | Innovent Announces Preliminary PoC data of IBI363 (PD-1/IL-2α-bias bispecific fusion protein) in Combination with Chemotherapy as First-line Treatment for Advanced NSCLC, Showing Encouraging Efficacy Signals and Favorable Safety

Therefore, the first cycle of 3 mg/kg IBI363 could initiate the immune system to expand effector T cells rapidly, enhance T cell infiltration, and form an IO-sensitive immune microenvironment. Subsequently, a 1.5 mg/kg every three weeks (Q3W) regimen is adopted for the maintenance treatment, which could

More news about: Innovent Biologics


May 21, 2026, 23:30 ET Mabwell Announces Latest Clinical Data on 9MW2821 to Be Presented at 2026 ASCO Annual Meeting as Oral and Poster Presentations

locally advanced or metastatic urothelial carcinoma (la/mUC) in the form of oral presentation, and the Phase II clinical study data of 9MW2821 in combination with toripalimab for perioperative muscle-invasive bladder cancer (MIBC) in the form of poster presentation. The Phase Ib/II clinical study of

More news about: Mabwell


May 21, 2026, 22:20 ET CERTAIN PUERTO RICO CLOSED-END FUNDS ANNOUNCE STRATEGIC REVIEW OF FUND STRUCTURE

organizations.In connection with the potential Fund mergers described herein, a surviving open-end fund would file a registration statement on Form N-14 that would include a proxy statement for the target closed-end Fund(s) and would constitute a prospectus of the surviving fund.  Other relevant

More news about: Certain Puerto Rico Funds


May 21, 2026, 22:01 ET CERTAIN PUERTO RICO CLOSED-END FUNDS ANNOUNCE STRATEGIC REVIEW OF FUND STRUCTURE

organizations.In connection with the potential Fund mergers described herein, a surviving open-end fund would file a registration statement on Form N-14 that would include a proxy statement for the target closed-end Fund(s) and would constitute a prospectus of the surviving fund.  Other relevant

More news about: Certain Puerto Rico Funds


May 21, 2026, 18:46 ET AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline

AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2025 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange

More news about: AbbVie


May 21, 2026, 18:30 ET STL announces US Conec certification to offer MMC pre-terminated solutions for AI-Data Center deployments

The MMC connector delivers 3X the cabling capacity of traditional MPO connectors, packing fibres into a Very Small Form Factor (VSFF), enabling maximum rack density, significantly more capacity, less cable congestion, and seamless scalability without consuming additional

More news about: Sterlite Technologies Ltd. (STL)


May 21, 2026, 17:23 ET Nuvalent Highlights Upcoming Data Presentations for Neladalkib and Zidesamtinib at the 2026 American Society of Clinical Oncology Annual Meeting

property. These and other risks and uncertainties are described in greater detail in the section entitled "Risk Factors" in Nuvalent's Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, as well as any prior and subsequent filings with the Securities and Exchange Commission. In addition, any

More news about: Nuvalent, Inc.


May 21, 2026, 17:17 ET Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress

products; and other risks described from time to time in Rigel's filings with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 and subsequent filings. Any forward-looking statement contained in this press release speaks only as of the

More news about: Rigel Pharmaceuticals, Inc.


May 21, 2026, 17:05 ET Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload

forward-looking statements are included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, including under the caption "Item 1A. Risk Factors," and in Whitehawk's subsequent Quarterly Reports on Form 10-Q, and elsewhere in Whitehawk's reports and other documents that Whitehawk

More news about: Whitehawk Therapeutics, Inc.


May 21, 2026, 17:00 ET Boehringer Ingelheim's oncology portfolio shows strong promise across multiple cancers at ASCO 2026

Your healthcare provider will do a pregnancy test before you start treatment with HERNEXEOSUse an effective form of birth control (contraception) during treatment with HERNEXEOS and for 2 weeks after your last doseTalk to your healthcare provider about

More news about: Boehringer Ingelheim


May 21, 2026, 17:00 ET Lilly to showcase oncology portfolio across tumor types and treatment modalities at the 2026 American Society of Clinical Oncology Annual Meeting

further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking

More news about: Eli Lilly and Company


May 21, 2026, 16:58 ET Sagrada Família to Inaugurate Tower of Jesus Christ on June 10, 2026, Marking 100 Years Since Antoni Gaudí's Death

the cross was installed on February 20, 2026, marking a decisive step toward the completion of the Basilica's central tower. He also described the form, materials and symbolism of the tower's pinnacle and cross, noting that work is continuing on the internal cladding and that the figure of The Lamb of

More news about: Sagrada Família


May 21, 2026, 16:54 ET Positive topline results from the pivotal Phase 3 REDUCE 2 study of pozdeutinurad in gout

at month 6. Secondary endpoints included a reduction in flares and tophi over time, and safety.About goutGout is the most common form of inflammatory arthritis and is caused by elevated levels of uric acid that accumulate in joints and other tissues, leading to painful flares. If left

More news about: Swedish Orphan Biotrauma AB


May 21, 2026, 16:51 ET Positive topline results from the pivotal Phase 3 REDUCE 2 study of pozdeutinurad in gout

at month 6. Secondary endpoints included a reduction in flares and tophi over time, and safety.About goutGout is the most common form of inflammatory arthritis and is caused by elevated levels of uric acid that accumulate in joints and other tissues, leading to painful flares. If left

More news about: Swedish Orphan Biotrauma AB


May 21, 2026, 16:30 ET MFI Received Nasdaq Notification Regarding Filing Rule Deficiency

annual report on Form 20-F for the year ended December 31, 2025 (the "Form 20-F"). The Filing Rule requires a company that listed on the Nasdaq Capital Market to timely file all required periodic financial reports on or before the date they are required to be filed. The Company filed a Form 12b-25 (the "NT

More news about: mF International Limited


May 21, 2026, 16:15 ET AZZ Inc. Announces June Investor Conference Schedule

provided additional information regarding risks associated with the business, including in Part I, Item 1A. Risk Factors, in AZZ's Annual Report on Form 10-K for the fiscal year ended February 28, 2026, and other filings with the SEC, available for viewing on AZZ's website at

More news about: AZZ, Inc.


May 21, 2026, 16:15 ET Webull Reports First Quarter 2026 Financial Results

http://www.sec.gov, where Webull will, among others, be filing reports, such as Reports on Form 6-K and its Annual Report on Form 20-F.ContactsFor [email protected]

More news about: Webull Corporation


May 21, 2026, 16:10 ET Allergan Aesthetics Receives Positive CHMP Opinion for Boey® (TrenibotulinumtoxinE) for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults

operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2025 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange

More news about: AbbVie


May 21, 2026, 16:05 ET Lam Research Corporation Declares Quarterly Dividend

the Securities and Exchange Commission, including specifically the Risk Factors described in our most recent annual report on Form 10-K or subsequent quarterly report on Form 10-Q. These uncertainties and changes could materially affect the forward-looking statements and cause actual results to vary

More news about: Lam Research Corporation


May 21, 2026, 16:05 ET Azenta Publishes 2025 Environmental, Social, and Governance (ESG) Report

with the Securities and Exchange Commission, including the "Risk Factors" section of the Company's most recent Annual Report on Form 10‑K and subsequent Quarterly Reports on Form 10‑Q.Forward‑looking statements speak only as of the date of this release. Azenta undertakes no obligation to publicly

More news about: Azenta


Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.